Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed

Environmental Toxicology and Chemistry

Volumn 29, Issue 1, 2010, Pages 79-89

  Metcalfe, Chris D ^a   Chu, Shaogang ^a   Judt, Colin ^a   Li, Hongxia ^a   Oakes, Ken D ^b   Servos, Mark R ^b   Andrews, David M ^c  

^a TRENT UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c Regional Municipality of Waterloo   (Canada)

Author keywords

Antidepressants; Bioaccumulation; Drinking water; Wastewater

Indexed keywords

BIOACCUMULATION; BIOCHEMICAL OXYGEN DEMAND; BIOCHEMISTRY; BIOMOLECULES; DRUG PRODUCTS; LANDFORMS; METABOLISM; METABOLITES; POTABLE WATER; RIVERS; WASTEWATER; WASTEWATER RECLAMATION; WASTEWATER TREATMENT; WATER TREATMENT PLANTS; WATERSHEDS;

ACTIVE METABOLITES; AQUATIC ENVIRONMENTS; BUPROPION; CITALOPRAM; DEMETHYLATION; DRINKING WATER; FATHEAD MINNOW; FLUOXETINE; MUNICIPAL WASTEWATER TREATMENT PLANTS; MUNICIPAL WASTEWATERS; ONTARIO , CANADA; PARENT COMPOUNDS; PAROXETINE; PIMEPHALES PROMELAS; REMOVAL RATE; RIVER WATER SAMPLES; RIVER WATERSHEDS; SERTRALINE; TARGET ANALYTES; TREATMENT PLANTS; URBAN WATERSHED; VENLAFAXINE; WET WEIGHT;

WATER RECYCLING;

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DRINKING WATER; DRUG METABOLITE; FLUOXETINE; PAROXETINE; RIVER WATER; SERTRALINE; VENLAFAXINE; WATER POLLUTANT;

BIOACCUMULATION; CONCENTRATION (COMPOSITION); CYPRINID; DRINKING WATER; DRUG; METABOLITE; RIVER WATER; WASTEWATER; WATER QUALITY; WATERSHED;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUATIC ENVIRONMENT; ARTICLE; BIOACCUMULATION; BIOLOGICAL ACTIVITY; CANADA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEMETHYLATION; ENVIRONMENTAL IMPACT ASSESSMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLITE; NONHUMAN; PIMEPHALES PROMELAS; POLLUTION MONITORING; POLLUTION TRANSPORT; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URBAN AREA; WASTE COMPONENT REMOVAL; WASTE WATER TREATMENT PLANT; WATER CONTAMINATION; WATER SAMPLING; WATERSHED; ANALYSIS; ANIMAL; CHEMISTRY; CYPRINIFORMES; LIQUID CHROMATOGRAPHY; METABOLISM; RISK ASSESSMENT; RIVER; SEWAGE; WATER MANAGEMENT; WATER POLLUTANT;

CANADA; GRAND RIVER [ONTARIO]; ONTARIO [CANADA];

PIMEPHALES PROMELAS;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHROMATOGRAPHY, LIQUID; CYPRINIDAE; MALE; RISK ASSESSMENT; RIVERS; TANDEM MASS SPECTROMETRY; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL; WATER PURIFICATION;

EID: 77249115315     PISSN: 07307268     EISSN: 15528618     Source Type: Journal    
DOI: 10.1002/etc.27     Document Type: Article

References (40)

1. Metcalfe CD, Miao XS, Koenig BG, Struger J. 2003. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environ Toxicol Chem 22: 2881-2889.
2. Kolpin DW, Skopec M, Meyer MT, Furlong ET, Zaugg SD. 2004. Urban contribution of pharmaceuticals and other organic wastewater contaminants to streams during differing flow conditions. Sci Total Environ 328: 119-130.
3. Jones OAH, Voulvoulis N, Lester JN. 2005. Human pharmaceuticals in wastewater treatment processes. Crit Rev Environ Sci Technol 35: 401-427.
4. Lishman L, Smyth SA, Sarafin K, Kleywegt S, Toito J, Peart T, Lee B, Servos M, Beland M, Seto P. 2006. Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. Sci Total Environ 367: 554-558.
5. Focazio MJ, Kolpin DW, Barnes KK, Furlong ET, Meyer MT, Zaugg SD, Barber LB, Thurman ME. 2008. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States-II. Untreated drinking water sources. Sci Total Environ 402: 201-216.
6. Jones OAH, Lester JN, Voulvoulis N. 2005. Pharmaceuticals: A threat to drinking water? Trends Biotechnol 23: 163-167.
7. Hua W, Bennett ER, Letcher RJ. 2006. Ozone treatment and the depletion of detectable pharmaceuticals and atrazine herbicide in drinking water sources from the upper Detroit River, Ontario, Canada. Water Res 40: 2259-2266.
8. Servos MR, Smith M, McInnis R, Burnison BK, Lee B-H, Seto P, Backus S. 2007. The presence of selected pharmaceuticals and the antimicrobial triclosan in drinking water in Ontario, Canada. Water Qual Res J Canada 42: 130-137.
9. Lamas JP, Salgado-Petinal C, Garcia-Jares C, Llompart M, Cela R, Gomez M. 2004. Solid-phase microextraction-gas chromatographymass spectrometry for the analysis of selective serotonin reuptake inhibitors in environmental water. J Chromatogr A 1046: 241-247.
10. Vasskog T, Berger U, Samuelsen PJ, Kallenborn R, Jensen E. 2006. Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromso, Norway. J Chromatogr A 1115: 187-195.
11. Himmelsbach M, Buchberger W, Klampfl CW. 2006. Determination of antidepressants in surface and waste water samples by capillary electrophoresis with electrospray ionization mass spectrometric detection after preconcentration using off-line solid-phase extraction. Electrophoresis 27: 1220-1226.
12. Schultz MM, Furlong ET. 2008. Trace analysis of antidepressant pharmaceuticals and their select degradates in aquatic matrixes by LC/ESI/MS/MS. Anal Chem 80: 1756-1762.
13. Lajeunesse A, Gagnon C, Sauve S. 2008. Determination of basic antidepressants and their N-desmethyl metabolites in raw sewage and wastewater using solid-phase extraction and liquid chromatographytandem mass spectrometry. Anal Chem 80: 5325-5355.
14. Brooks BW, Chambliss CK, Stanley JK, Ramirez A, Banks KE, Johnson RD, Lewis RJ. 2005. Determination of select anti-depressants in fish from an effluent dominated stream. Environ Toxicol Chem 24: 464-469.
15. Chu S, Metcalfe CD. 2007. Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry. J Chromatogr A 1163: 112-118.
16. Ramirez AJ, Brain RA, Usenko S, Mottaleb MA, O'Donnell JG, Stahl LL, Wathen JB, Snyder BD, Pitt JL, Perez-Hertado P, Dobbins LL, Brooks BW, Chambliss CK. Occurrence of pharmaceuticals and personal care products (PPCPs) in fish tissues. Results of a national pilot study in the U. S. Environ Sci Technol (in press).
17. Hiemke C, Hartter S. 2000. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Therap 85: 11-28.
18. Vanderford BJ, Snyder SA. 2006. Analysis of pharmaceuticals in water by isotope dilution liquid chromatography/tandem mass spectrometry. Environ Sci Technol 40: 7312-7320.
19. Hao C, Lissemore L, Nguyen B, Kleywegt S, Yang P, Solomon K. 2006. Determination of pharmaceuticals in environmental waters by liquid chromatography/electrospray ionization/tandem mass spectrometry. Anal Bioanal Chem 384: 505-513.
20. Zhao X, Metcalfe CD. 2008. Characterizing and compensating for matrix effects using atmospheric pressure chemical ionization liquid chromatography-tandem mass spectrometry: Analysis of neutral pharmaceuticals in municipal wastewater. Anal Chem 80: 2010-2017.
21. Alder AC, Bruchet A, Carballa M, Clara M, Joss A, Loffler D. 2006. Consumption and occurrence. In Ternes TA, Joss A, eds, Human Pharmaceuticals, Hormones and Fragrances: The Challenge of Micropollutants in Urban Water Management. IWA, London, UK, pp 74-87.
22. Al-Ahmad A, Daschner FD, Kummerer K. 1999. Biodegradability of cefotiam, ciprofloxacin, meropenem, penicillin G, and sulfamethoxazole and inhibition of wastewater bacteria. Arch Environ Contam Toxicol 37: 158-167.
23. Howell SR, Husbands GEM, Scatina GA, Sisenwine SF. 1993. Metabolic disposition of super (14) C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23: 349-359.
24. Dalgaard L, Larsen C. 1999. Metabolism and excretion of citalopram in man: Identification of O-acyl and N-glucuronides. Xenobiotica 29: 1033-1041.
25. Warrington SJ, Ronfeld RA, Wilner KD, Lazar JD. 1992. Human pharmacokinetics of sertraline. Clin Neuropharmacol 15: 54-55.
26. Benfield P, Heel RC, Lewis SP. 1986. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 481-508. (Pubitemid 17190279)
27. Schroeder DH. 1983. Metabolism and kinetics of bupropion. J Clin Psychiatry 15: 79-781.
28. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Greb WH. 1989. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 80: 60-75.
29. Mintzes B, Bassett K, Wright JM. 2002. Drug safety without borders: Concerns about bupropion. Can Med Assoc J 167: 447.
30. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, Potter WZ. 1988. Bupropion in depression: The role of metabolites in clinical outcome. Arch Gen Psychiatry 45: 145-149.
31. Hesse LM, Venkstakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. 2000. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab Disp 28: 1176-1182.
32. Ronfeld RA, Tremaine LM, Wilner KD. 1997. Pharmacokientics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32: 22-30.
33. Baumann P. 1998. Care of depression in the elderly: Comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 13: S35-S43.
34. Nakamura Y, Yamamoto H, Sekizawa J, Kondo T, Hirai N, Tatarakazo N. 2008. The effects of pH in Japanese medaka (Oryzias latipes) : Acute toxicity in fish larvae andbioaccumulation injuvenile fish. Chemosphere 70: 865-873.
35. Paterson G, Metcalfe CD. 2008. Uptake and depuration of the antidepressant, fluoxetine by the Japanese medaka (Oryzias latipes). Chemosphere 74: 125-130.
36. Huggett DB, Ericson JF, Cook JC, Williams RT. 2004. Plasma concentrations of human pharmaceuticals as predictors of pharmacological responses in fish. In Kummerer K, ed, Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer, Berlin, Germany, pp 373-385.
37. Christensen AM, Faaborg-Andersen S, Ingerslev F, Baun A. 2006. Mixture and single substance toxicity of selective serotonin reuptake inhibitors toward algae and crustaceans. Environ Toxicol Chem 26: 85-91.
38. Henry TB, Black MC. 2006. Mixture and single substance acute toxicity of selective serotonin reuptake inhibitors in Ceriodaphnia dubia. Environ Toxicol Chem 26: 1751-1755.
39. Flaherty CM, Dobson SI. 2005. Effects of pharmaceuticals on Daphnia survival, growth, and reproduction. Chemosphere 61: 200-207.
40. Stackelberg PE, Furlong ET, Meyer MT, Zaugg SD, Henderson AK, Reismann DB. 2004. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water treatment plant. Sci Total Environ 329: 99-113.